UNASSIGNED: A national @entity99 therapy program was launched in Taiwan in October 2003. This study aimed to assess the impact of the program on @entity3851 ( @entity3851 ) burden. Profiles of national registries of households, @entity5 , and death certificates were used to derive incidence and mortality of ESLDs from 2000 to 2011. Age-gender-adjusted incidence and mortality rates of @entity157 ( @entity157 ) and @entity409 ( @entity409 ) and @entity82 of adults ages 30-69 years were compared before and after launching the program using Poisson's regression models. A total of 157,570 and 61,823 @entity1 (15%-25% of those eligible for reimbursed treatment) received therapy for chronic @entity1956 and C, respectively, by 2011. There were 42,526 @entity409 and @entity82 deaths, 47,392 @entity157 deaths, and 74,832 incident @entity157 cases occurred in 140,814,448 @entity1 -years from 2000 to 2011. Male gender and elder age were associated with a significantly increased risk of @entity409 and @entity82 and @entity157 . Mortality and incidence rates of ESLDs decreased continuously from 2000 to 2003 (before therapy program) through 2004-2007 to 2008-2011 in all age and gender groups. The age-gender-adjusted rate ratio (95% confidence interval; P value) in 2008-2011 was 0.78 (0.76-0.80; P   <   0.001) for @entity409 and @entity82 mortality, 0.76 (0.75-0.78; P   <   0.005) for @entity157 mortality, and 0.86 (0.85-0.88; P   <   0.005) for @entity157 incidence using 2000-2003 as the reference period (rate ratio   =   1.0). Conclusions: The national @entity99 therapy program has significantly reduced the mortality of @entity409 and @entity82 and incidence and mortality of @entity157 . (Hepatology 2014).

Significant reduction in end-stage XXXX burden through the national @entity99 therapy program in Taiwan.

@entity1 :: ('9606', 'Species') :: ['patients', 'person'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity1956 :: ('MESH:D006509', 'Disease') :: ['hepatitis B'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers'] @entity409 :: ('MESH:D008107', 'Disease') :: ['chronic liver diseases', 'CLDs'] @entity3851 :: ('MESH:D058625', 'Disease') :: ['reduction of end-stage liver disease', 'ESLD'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma'] @entity99 :: ('MESH:D056486', 'Disease') :: ['viral hepatitis']
@entity409 :: (MESH:D008107,Disease) :: ['liver diseases']
